85 related articles for article (PubMed ID: 12218879)
41. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS.
Lawrinson P; Ali R; Buavirat A; Chiamwongpaet S; Dvoryak S; Habrat B; Jie S; Mardiati R; Mokri A; Moskalewicz J; Newcombe D; Poznyak V; Subata E; Uchtenhagen A; Utami DS; Vial R; Zhao C
Addiction; 2008 Sep; 103(9):1484-92. PubMed ID: 18636999
[TBL] [Abstract][Full Text] [Related]
42. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
43. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.
Anchersen K; Clausen T; Gossop M; Hansteen V; Waal H
Addiction; 2009 Jun; 104(6):993-9. PubMed ID: 19392907
[TBL] [Abstract][Full Text] [Related]
44. [Substitution treatment for opiate dependence: survey of community pharmacies in Aquitaine].
Jeantaud I; Haramburu F; Bégaud B
Therapie; 1999; 54(2):251-5. PubMed ID: 10394262
[TBL] [Abstract][Full Text] [Related]
45. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
Bell J; Mutch C
Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
[TBL] [Abstract][Full Text] [Related]
46. Low efficacy of non-opioid drugs in opioid withdrawal symptoms.
Hermann D; Klages E; Welzel H; Mann K; Croissant B
Addict Biol; 2005 Jun; 10(2):165-9. PubMed ID: 16191669
[TBL] [Abstract][Full Text] [Related]
47. Public policy statement on buprenorphine for opiate dependence and withdrawal.
J Addict Dis; 2004; 23(4):116-7. PubMed ID: 15534969
[No Abstract] [Full Text] [Related]
48. Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status.
Kornør H; Waal H; Sandvik L
Drug Alcohol Rev; 2007 Mar; 26(2):135-41. PubMed ID: 17364848
[TBL] [Abstract][Full Text] [Related]
49. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
[TBL] [Abstract][Full Text] [Related]
50. Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.
De S; Jain R; Ray R; Dhawan A; Varghese ST
Indian J Physiol Pharmacol; 2008; 52(1):53-63. PubMed ID: 18831352
[TBL] [Abstract][Full Text] [Related]
51. [Questionnaire study of general practitioners regarding experience and attitude to opioid substitution therapy].
Mravcík V; Coufalová M; Popov P; Zábranský T; Procházka R
Epidemiol Mikrobiol Imunol; 2005 Feb; 54(1):27-33. PubMed ID: 15810140
[TBL] [Abstract][Full Text] [Related]
52. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
[TBL] [Abstract][Full Text] [Related]
53. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
54. Buprenorphine prescription and the increased relative cost.
Alvarez FJ; Gonzalez-Saiz F
Addiction; 2005 Sep; 100(9):1373-4. PubMed ID: 16128729
[No Abstract] [Full Text] [Related]
55. [Risk factors of early drop-out during induction of high-dose buprenorphine substitution therapy. A study of 1085 opiate addicts].
Batel P; Reynaud-Maurupt C; Lavignasse P; Constant MV; Kopp P; Jourdain JJ; Videau B; Mucchielli A; Riff B; Lowenstein W
Presse Med; 2004 Oct; 33(18 Suppl):5-9. PubMed ID: 15617169
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion.
Lofwall MR; Wunsch MJ; Nuzzo PA; Walsh SL
J Subst Abuse Treat; 2011 Oct; 41(3):321-9. PubMed ID: 21664789
[TBL] [Abstract][Full Text] [Related]
57. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence.
Gisev N; Shanahan M; Weatherburn DJ; Mattick RP; Larney S; Burns L; Degenhardt L
Addiction; 2015 Dec; 110(12):1975-84. PubMed ID: 26212260
[TBL] [Abstract][Full Text] [Related]
58. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey.
Nordmann S; Frauger E; Pauly V; Orléans V; Pradel V; Mallaret M; Thirion X; Micallef J
Pharmacoepidemiol Drug Saf; 2012 Feb; 21(2):184-90. PubMed ID: 22109894
[TBL] [Abstract][Full Text] [Related]
59. [Acute poisoning during substitution therapy based on high-dosage buprenorphine. 29 clinical cases--20 fatal cases].
Tracqui A; Tournoud C; Flesch F; Kopferschmitt J; Kintz P; Deveaux M; Ghysel MH; Marquet P; Pépin G; Petit G; Jaeger A; Ludes B
Presse Med; 1998 Mar; 27(12):557-61. PubMed ID: 9767947
[TBL] [Abstract][Full Text] [Related]
60. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States.
Barnett PG; Zaric GS; Brandeau ML
Addiction; 2001 Sep; 96(9):1267-78. PubMed ID: 11672491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
